Lupin gets tentative approval for Arformoterol Tartrate Inhalation Solution

Drug major Lupin on Wednesday (29 April) announced that it received tentative approval for its Arformoterol Tartrate Inhalation Solution from the US drug regulator.

Lupin announced that it has received tentative approval for its Arformoterol Tartrate Inhalation Solution 15 mcg (base)/2 mL, unit-dose Vials, from the United States Food and Drug Administration (USFDA) to market a generic version of Brovana Inhalation Solution, 15 mcg/2 mL of Sunovion Pharmaceuticals Inc. (Sunovion).

The solution is indicated for the long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. The drug had an annual sales of approximately $489 million in the US.

Lupin was up 0.04% to Rs 854.65. The scrip traded in the range of Rs 850 to Rs 872.75 so far during the day.

On a consolidated basis, Lupin reported a net loss of Rs 835 crore in Q3 December 2019 as against a net loss of Rs 151.75 crore in Q3 December 2018. Net sales declined 2.75% to Rs 3,716.09 crore in Q3 December 2019 over Q3 December 2018.

Lupin is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world. The firm offers products in the cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastro-intestinal, anti-infectives and non-steroidal anti-inflammatory drug therapy areas.

Powered by Capital Market - Live News